stoxline Quote Chart Rank Option Currency Glossary
  
Emmaus Life Sciences, Inc. (EMMA)
0.091  -0.001 (-1.09%)    06-12 11:08
Open: 0.091
High: 0.091
Volume: 5
  
Pre. Close: 0.092
Low: 0.091
Market Cap: 5(M)
Technical analysis
2023-05-19 4:37:13 PM
Short term     
Mid term     
Targets 6-month :  0.37 1-year :  0.41
Resists First :  0.31 Second :  0.35
Pivot price 0.3
Supports First :  0.25 Second :  0.21
MAs MA(5) :  0.31 MA(20) :  0.31
MA(100) :  0.35 MA(250) :  0.34
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  69.9 D(3) :  73.7
RSI RSI(14): 44.8
52-week High :  0.6 Low :  0.07
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ EMMA ] has closed above bottom band by 37.8%. Bollinger Bands are 34.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.3 - 0.3 0.3 - 0.3
Low: 0.25 - 0.26 0.26 - 0.26
Close: 0.3 - 0.3 0.3 - 0.3
Company Description

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

Headline News

Mon, 15 Apr 2024
Emmaus Life Sciences Reports Delayed Filing of Annual Report - PR Newswire

Fri, 02 Feb 2024
Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico - PR Newswire

Tue, 14 Nov 2023
Emmaus Life Sciences Reports Q3 2023 Financial Results - PR Newswire

Wed, 23 Aug 2023
Emmaus Life Sciences Reports Management Changes - PR Newswire

Tue, 02 Aug 2022
EMMA: A Stock with Upside Potential - Yahoo Finance

Thu, 04 Nov 2021
Emmaus Life Sciences signs agreement with Asembia to expand support services and access to prescription medicine ... - Proactive Investors UK

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
PNK
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 51 (M)
Shares Float 31 (M)
Held by Insiders 37.9 (%)
Held by Institutions 0 (%)
Shares Short 41 (K)
Shares Short P.Month 34 (K)
Stock Financials
EPS -0.21
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.69
Profit Margin -57.8 %
Operating Margin -35.9 %
Return on Assets (ttm) -7.9 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 96.4 %
Gross Profit (p.s.) 0
Sales Per Share 0.36
EBITDA (p.s.) -0.13
Qtrly Earnings Growth 0 %
Operating Cash Flow -5 (M)
Levered Free Cash Flow 4 (M)
Stock Valuations
PE Ratio -1.5
PEG Ratio 0
Price to Book value -0.44
Price to Sales 0.83
Price to Cash Flow -3.02
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-07-17
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android